Name | Lafutidine |
Synonyms | Lafutidine 118288-08-07 Adefovir Dipivioxil LAFUTIDINE(SUBJECTTOPATENTFREE) n-(4-(4-piperidinylmethyl)pyridyl-2-oxy)butenyl-2-(furfurylsulfinyl)acetamide (Z)-2-((Furan-2-ylmethyl)sulfinyl)-N-(4-((3-(piperidin-1-ylmethyl)pyridin-2-yl)oxy)but-2-en-1- (Z)-2-((Furan-2-ylmethyl)sulfinyl)-N-(4-((3-(piperidin-1-ylmethyl)pyridin-2-yl)oxy)but-2-en-1-yl) 2-((Furan-2-ylMethyl)sulfinyl)-N-(4-((4-(piperidin-1-ylMethyl)pyridin-2-yl)oxy)but-2-en-1-yl)acetaMide (Z)-2-((Furan-2-ylMethyl)sulfinyl)-N-(4-((3-(piperidin-1-ylMethyl)pyridin-2-yl)oxy)but-2-en-1-yl)acetaMide 2-[(furan-2-ylmethyl)sulfinyl]-N-[(2Z)-4-{[4-(piperidin-1-ylmethyl)pyridin-2-yl]oxy}but-2-en-1-yl]acetamide |
CAS | 118288-08-7 |
EINECS | 601-513-8 |
InChI | InChI=1/C22H29N3O4S/c26-21(18-30(27)17-20-7-6-14-28-20)23-9-2-5-13-29-22-15-19(8-10-24-22)16-25-11-3-1-4-12-25/h2,5-8,10,14-15H,1,3-4,9,11-13,16-18H2,(H,23,26)/b5-2- |
Molecular Formula | C22H29N3O4S |
Molar Mass | 431.55 |
Density | 1.252±0.06 g/cm3(Predicted) |
Melting Point | 92.7-94.9° |
Boling Point | 704.2±60.0 °C(Predicted) |
Flash Point | 379.7°C |
Water Solubility | Insoluble in water |
Solubility | DMSO 86 mg/mL Water <1 mg/mL Ethanol 13 mg/mL |
Vapor Presure | 1.12E-19mmHg at 25°C |
Appearance | White to beige powder |
Color | White to Orange to Green |
pKa | 13.13±0.46(Predicted) |
Storage Condition | Sealed in dry,Store in freezer, under -20°C |
Refractive Index | 1.598 |
MDL | MFCD00867520 |
Use | Drugs for digestive system |
Safety Description | 24/25 - Avoid contact with skin and eyes. |
HS Code | 29349990 |
melting point 92.7-94.9 °c. Soluble in DMF, acetic acid, soluble in methanol, almost insoluble in water.
The sodium hydride was suspended in Tetrahydrofuran, and a tetrahydrofuran solution of (Z) -4-tetrahydropyranoxy-2-butenol was added dropwise at room temperature, in turn add 2 chlorine 4 piperidyl methyl pyridine and dimethyl formamide, reaction is completed, after processing (Z) -4-piperidinylmethyl -2-(4-tetrahydropyridyloxy-2-butene-oxy) pyridine. The compound is dissolved in methanol, under cooling in an ice bath, P-toluenesulfonic acid monohydrate is added, and the reaction is stirred to obtain (z) -4-[4-(piperidinyl methyl) pyridin-2-oxy]-2-butenol. The compound and triethylamine were dissolved in toluene, and a toluene solution of methanesulfonyl chloride was added dropwise under cooling in an ice bath, stirred, and treated to give a solution. In 2 a toluene solution of furan methyl sulfinyl acetamide is added potassium tert-butoxide, drop plus surface obtained solution reaction, after treatment to obtain lafutidine.
lafutidine was jointly developed by Fuji (Fujire-bio) and Taiho companies in Japan and was launched in Japan in April 2000. It is a potent, long-acting second-generation histamine H2 receptor antagonist with a unique gastric protective effect. It can reduce the basal secretion of gastric acid and inhibit the gastric acid secretion stimulated by histamine, gastrin and urethane. Compared with cimetidine, famotidine and other similar drugs, the blocking effect on H2 receptor is more effective and lasting, so it has the advantage of anti-gastric acid secretion. Mainly for the treatment of gastric ulcer, duodenal ulcer and acute or chronic gastritis.